A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis.
OBJECTIVE
Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis.


METHODS
Multicenter clinical trial comparing levofloxacin 750 mg for 5 days vs levofloxacin 500 mg for 10 days.


RESULTS
Sinus fluid samples were obtained by antral puncture (59.2%) or by sinus endoscopy (40.8%). Among microbiologically evaluable patients, 91.4% (139/152) of patients receiving levofloxacin 750 mg achieved clinical success vs 88.6% (132/149) of patients receiving levofloxacin 500 mg (95% CI -10.0, 4.2). Clinical success rates by pathogen were above 90% in both treatment groups for the 3 typical pathogens of acute sinusitis: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The safety profile of the 2 dosage strengths was similar.


CONCLUSIONS
Levofloxacin 750 mg for 5 days is noninferior to levofloxacin 500 mg for 10 days.


CONCLUSIONS
Levofloxacin 750 mg for 5 days represents a safe and effective treatment regimen for acute bacterial sinusitis.


METHODS
A-1b.
Poole
Michael
M
Georgia Ear Institute, Savannah, Georgia, USA.
Anon
Jack
J
Paglia
Margaret
M
Xiang
Jim
J
Khashab
Mohammed
M
Kahn
James
J
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D011446:Prospective Studies; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin